|Year : 2022 | Volume
| Issue : 2 | Page : 87-93
CRP and its relation to cognitive performance in schizophrenia patients: a cross-sectional study
Sanaa Ahmed Kamal1, Sarah Adel Abdel-Monem El-Samahy1, Walaa Abdelfattah2, Ola Osama Khalaf1
1 Psychiatry, Department of Psychiatry, Faculty of Medicine, Cairo University, Cairo, Egypt
2 Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt
|Date of Submission||24-Oct-2021|
|Date of Decision||29-Nov-2021|
|Date of Acceptance||20-Dec-2021|
|Date of Web Publication||24-Jun-2022|
Ola Osama Khalaf
Psychiatry, Department of Psychiatry, Faculty of Medicine, Cairo University, Cairo, Postal Code 11562
Source of Support: None, Conflict of Interest: None
Background Schizophrenia (SZ) is one of the most severe and chronic forms of mental illness. It involves cognition, emotion, perception, and behavior. There is an obvious role of neuroinflammation and immunogenetics in SZ. There is a relation between the severity of cognitive deficits and enhanced levels of inflammatory markers in schizophrenic patients, including C-reactive protein (CRP). Also, a relation between CRP and the negative-symptom subscale of Positive and Negative Syndrome Scale (PANSS) was observed.
Aims To study the relation between CRP level with different cognitive domains in patients with SZ and its relation to the psychopathology of SZ.
Methods A cross-sectional study was applied on 40 SZ patients and 40 healthy controls, serum CRP was measured, and they were cognitively assessed using Arabic version of Montreal Cognitive Assessment Basic (MoCA-B).
Results SZ patients showed worse cognitive performance on all subtests (except orientation), MOCA-B, and the total score when compared with normal controls. A negative correlation between executive functions, calculation, abstraction, memory, naming, and attention subtests of MoCA-B and its total score with the serum CRP was found. A positive correlation between CRP and the negative subscale and total score of PANSS was found.
Conclusions Serum CRP level was elevated in patients with SZ when compared with healthy controls and significantly negatively correlated with cognitive functions, and positively correlated with negative symptoms in SZ patients, which seconds the neuroinflammatory etiology of SZ.
Keywords: cognition, cognitive disorders, CRP, MoCA-B, psychopathology PANSS, schizophrenia
|How to cite this article:|
Kamal SA, El-Samahy SA, Abdelfattah W, Khalaf OO. CRP and its relation to cognitive performance in schizophrenia patients: a cross-sectional study. Egypt J Psychiatr 2022;43:87-93
|How to cite this URL:|
Kamal SA, El-Samahy SA, Abdelfattah W, Khalaf OO. CRP and its relation to cognitive performance in schizophrenia patients: a cross-sectional study. Egypt J Psychiatr [serial online] 2022 [cited 2023 Sep 29];43:87-93. Available from: https://new.ejpsy.eg.net//text.asp?2022/43/2/87/348152
| Introduction|| |
Schizophrenia (SZ) is one of the most severe and chronic forms of mental illness. It involves cognition, emotion, perception, and behavior (Minzenberg et al., 2008). SZ affects nearly 1% of the world’s population (Oertel-Knöchel et al., 2011). It is estimated that the number of persons in Egypt with SZ would be within 0.5–1.5 million, with the current population-growth rate, these figures will double in about 40 years and be tenfold in 140 years (Zahran et al., 2006).
Many etiological hypotheses for SZ have been suggested such as the neurodevelopmental, neurodegenerative, immunological, inflammatory, and the infectious hypothesis (Lakhan et al., 2010). There is evidence for the role of neuroinflammation and immunogenetics in SZ, as there is an increase of serum concentration of several proinflammatory cytokines (Potvin et al., 2008; Monji et al., 2009).
Also, inflammation has been suggested to play a role in the regulation of cognition in physiological conditions, especially the effect of peripheral and central inflammatory mediators (i.e., cytokines) on learning and memory abilities (Fourrier et al., 2019).
A recent systemic review conducted on SZ patients reported an association between plasma C-reactive protein (CRP) levels and worse cognitive performance, including the domains of attention, memory, and learning abilities (Fourrier et al., 2019). CRP is a pentameric protein that is generated in the liver and secreted in the blood. The measurement of CRP in the blood provides a reliable marker of chronic inflammation caused by infectious and other inflammatory agents (Dickerson et al., 2013). It is considered to be a risk factor for the cardiovascular diseases, diabetes, and other metabolic dysfunction when elevated in the blood. It is also known to be associated with depression and cognitive impairment (Singh and Chaudhuri, 2014).
There is evident positive correlation between the severity of cognitive deficits and enhanced levels of inflammatory markers in schizophrenic patients, including CRP (Meyer et al., 2011). Several studies were done to investigate the association between the level of CRP and cognitive impairment in patients with SZ.
In a study carried out in Texas involving 39 patients with SZ, a positive correlation was observed between CRP and the Positive and Negative Syndrome Scale (PANSS) negative-symptom subscale, PANSS general psychopathology subscale, and total PANSS score, but there was no correlation between CRP and positive symptoms (Boozalis et al., 2018).
So, from the above-mentioned data, we hypothesized that (a) elevated levels of CRP in SZ patients are associated with worse cognitive performance than in normal controls. (b) High CRP is associated with more severe psychopathology, and accordingly, the aim of our study is to study the relation between CRP level with different cognitive domains in patients with SZ and its relation to the psychopathology of SZ.
| Materials and methods|| |
This study is a case–control cross-sectional study and the sample included was a convenient one. It was conducted from October 2019 to March 2020. It consisted of 80 participants divided into two equal groups: patients’ group (no.=40 patients) and healthy-control group (no.=40 patients). They were recruited from both the inpatient unit and outpatient clinic of Psychiatry and Addiction Prevention Hospital, Kasr Al-Ainy Hospitals, Faculty of Medicine, Cairo University.
Inclusion criteria included the following: participants were consenting to participate in the research (informed written consent) and their consented data would be used in research purposes, male and female patients aged between 20 and 30 years, diagnosis of SZ meeting the criteria in Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV), and can read and write. All were being treated with atypical antipsychotic medications at the time of data collection.
Any patients having acute infections or a primary inflammatory condition such as tuberculosis, current use of corticosteroids or immunosuppressive drugs, having autoimmune disorders such as rheumatoid disorder, any substance abuse or dependence, prior diagnosis of cognitive disorders, clinically significant neurological disorder that would affect cognitive performance such as epilepsy or encephalitis, significant head trauma, clinically below-average intelligence, history of electroconvulsive therapy for the past 3 months, or pregnancy were excluded from the study.
Forty healthy controls were recruited from volunteers working in Kasr Al-Ainy hospitals and matched for age, education, and sociodemographics. The same inclusion and exclusion criteria as the patient group were ensured while recruiting them.
Sample collection and CRP measurement: fresh peripheral blood was collected from all participants by a sterile venipuncture and added to serum-separator vacutainer tubes. Serum samples were freshly separated by centrifugation at 2000 rpm for 10–20 min and kept frozen at −20°C, until the time of the assay. Serum CRP was measured using the quantitative enzyme-linked immunosorbent assay (ELISA) technique by “Human C-Reactive Protein, CRP ELISA Kit; From Chongqing Biopsies Co., Ltd; China” catalog number BYEK1124, according to the manufacturer’s instructions.
Patients were clinically interviewed using the clinical sheet of the psychiatry department of Kasr Al-Ainy Hospital, Faculty of Medicine, Cairo University. It was used for collection of sociodemographic variables and detailed clinical history. Also, we used the SZ section of the Structured Clinical Interview for DSM-IV Disorders (First et al., 1997) in its Arabic version (El Missiry et al., 2004) to confirm the diagnosis. Patients’ group was subjected to PANSS (Kay et al., 1987), which consists of positive, negative, and general psychopathlogy subscales.
In addition, the Arabic version of Montreal Cognitive Assessment Basic (MoCA-B) was used to assess six cognitive domains: visual perception (superimposed objects), executive functioning (simplified alternating trail making, word similarity, and problem solving), language (fruit fluency and animal naming), attention (modified digit Stroop), memory (five-word delayed recall), and orientation (time and place) (Saleh et al., 2019). It was published in the official website of Montreal Cognitive Examinations in May 2016 (http://www.mocatest.org) and the use of this test in patients with SZ was tested before (Fisekovic et al., 2012; Yang et al., 2018).
The Arabic version of the General Health Questionnaire-12 (Daradkeh et al., 2001) was applied to the control group to exclude the presence of any psychiatric illness. It is a self-report instrument for the detection of mental disorders in the community.
Statistical analysis: data were summarized using mean and SD in quantitative data and using frequency (count) and relative frequency (percentage) for categorical data. Comparisons between quantitative variables were done using parametric t-tests for continuous variables and were expressed as mean±SD and the nonparametric test Mann–Whitney test. For comparing categorical data, χ2 test was performed. Correlations were done using Spearman correlation coefficient. P values less than 0.05 were considered as statistically significant.
Ethical approval: the research ethics committee (REC) of Faculty of Medicine, Cairo University, has approved the study protocol in August 2019 with code no.: MS-146-2019.
| Results|| |
Demographic data and clinical characteristics of patients and controls groups are summarized in [Table 1]. There was a significant difference between the two groups as regards working, marital status, smoking, and serum CRP level. The duration of illness ranged from 1 year to 11 years with a mean of 5.01 years (±2.79).
[Table 2] shows the patient scores (expressed as mean and ±S.D.) on general psychopathology subscale, positive subscale, negative subscale, and total score of PANSS.
When we compared the patients’ group with controls, the former showed worse cognitive performance on all subtests (except orientation) of MOCA-B and the total score as shown in [Table 3].
|Table 3 Comparison between both groups as regards MOCA-B subtests and total score|
Click here to view
Then, we correlated serum CRP level with PANSS scores and there was a positive statistically significant correlation with the negative subscale of PANSS and the total PANSS score as shown in [Table 4].
|Table 4 Correlation between serum CRP level with PANSS scores, MoCA-B subtests, and total score|
Click here to view
In addition, there were statistically significant negative correlations between executive functions, calculation, abstraction, memory, naming, and attention subtests of MoCA-B and its total score with the serum CRP level as shown in [Table 4]. This means that patients who have high serum CRP levels showed poorer performance on assessment of these cognitive domains.
Finally, by multivariate linear regression with total MOCA as the dependent variable and duration of illness, age, sex, smoking, and CRP as independent predictors, we found that there was a significant inverse relation between MoCA-B and CRP after adjustment for the duration of illness, age, sex, and smoking as possible confounders.
| Discussion|| |
To our knowledge, this is considered to be the first study in Egypt that investigated the relation between serum CRP with different cognitive domains using MoCA-B, all with the severity of symptoms in a sample of patients suffering from SZ.
The mean duration of illness was 5.01 years as we aimed to limit the age of patients between 20 and 30 years to reduce the confounding effects of aging and duration of illness on the cognitive functions. It was taken into consideration that tests of memory performance and executive functioning have been found to show decline beyond the age of 50 (Horning and Davis, 2012). Also, longer duration of illness was associated with memory deficits (visual, auditory, and verbal), executive function, motor, and processing-speed deficits (Sponheim et al., 2010).
A higher serum CRP was among the patients’ group when compared with the controls, these results were consistent with multiple previous studies. One study stated that patients with SZ, when compared with healthy controls, showed higher serum CRP levels together with higher CD4+/CD8+ ratio and lymphocytes with morphological abnormalities (Mazzarello et al., 2004). Solanki et al. (2009) and Mazzarello et al., (2004) concluded that patients with SZ had significantly higher serum CRP level when compared with healthy controls. Similar results (Solanki et al., 2009) also suggested that the elevated CRP may act as a causal risk for SZ. Two meta-analysis studies were previously done to verify whether serum CRP levels are indeed increased in SZ and they stated that patients with SZ showed higher serum CRP levels than healthy controls (Miller et al., 2013; Fernandes et al., 2016).
So, the presence of CRP is probably state-dependent expression of nonspecific humoral immune alteration in schizophrenic patients (Ohaer et al., 1993) and these findings support the notion that there is a possible neuroinflammatory etiology in SZ (Fourrier et al., 2019).
Cognitive functions were assessed using MoCA-B, its use to assess cognitive functions in SZ was validated in previous studies (Yang et al., 2018; Gil-Berrozpe et al., 2020). Patients’ group showed poorer cognitive performance than controls as regards executive functions, verbal fluency, calculation, abstraction, memory, visuospatial abilities, naming, and attention subtests of MoCA-B. These results are concordant to the results of the meta-analysis conducted by Fioravanti et al. (2012), which assessed cognitive functioning in SZ and showed a statistically significant poorer performance than controls on tests applied to assess attention and executive functions.
The calculation and naming subtests of MoCA-B were considered as parts of the executive functions as evidenced by the Modified Six Elements Test used to assess executive functions and contain subtests for simple arithmetic and simple naming functions (Liu et al., 2011)
Abstraction is also considered as a dimension of executive functions and is assessed with a proverb test as a part of Delis–Kaplan Executive Function System in a previous study (Savla et al., 2012) and also assessed with word similarities (Akbar et al., 2019) as in MoCA-B. So, in the present study, executive functions were found to be the most commonly observed cognitive deficits in SZ patients as in Orellana and Slachevsky (2013).
Verbal fluency was less in the SZ group than in the control group. This is consistent with a Brazilian study that enrolled 141 patients with SZ and 119 healthy controls, the results showed deficits in verbal fluency in the SZ group where they generated fewer total words than the controls (Berberian et al., 2016), and this could be explained by the poverty of speech as one of the negative symptoms in SZ. Brébion et al. (2013) stated that verbal-fluency deficit in patients with SZ was found to be associated with more negative symptoms and attention disorders.
Memory when assessed by the memory subtest of MoCA-B was worse in the SZ group than in the control one. This was consistent with a meta-analysis study (Aleman et al., 1999), which showed a significant memory impairment in SZ and it was not affected by age, medication, duration of illness, patient status, and severity of psychopathology.
Visuospatial abilities were also statistically significantly lower in patients with SZ than in controls, which was consistent with a Greece study conducted on 70 patients with SZ and 42 healthy controls and underwent a battery of neuropsychological tests, including a test for visuospatial abilities. Increased difficulties in visuospatial abilities were detected (Bozikas et al., 2006).
Attention subtest of MoCA-B was statistically significant lower in patients’ group when compared with the controls. This is consistent with a study in which 48 patients with SZ and 48 healthy controls were enrolled and underwent the Stroop Coloured Word Test (SCWT), the Digit Vigilance Test (DVT), the Symbol Digit Modalities Test (SDMT), the Backward Digit Span Test, and the Colour Trails Test to assess selective attention, sustained attention, switching attention, and attentional-control processing. The results of the mentioned study showed that patients with SZ performed poorer on SCWT, DVT, and SDMT relative to healthy controls (Chan et al., 2004).
As regards the statistically negative correlation between the serum CRP level and the MoCA-B total score and its subtest scores for executive functions, calculation, abstraction, memory, naming, and attention could be understood by the higher levels of serum CRP that was associated with dysexecutive syndrome and a cerebral microstructure disintegration in frontal pathways (Wersching et al., 2010; Fraguas et al., 2014).
These findings were consistent with Misiak et al. (2018), who conducted a systematic review to investigate the association between peripheral levels of cytokines and CRP and cognition in patients with SZ and bipolar disorder, the study showed that most consistent results indicate worse cognitive performance in SZ patients with higher CRP levels. Our findings were also in line with multiple earlier studies (Diyanoosh et al., 2012; Bulzacka et al., 2016). In contrast, these results were inconsistent with Joseph et al. (2015), who concluded that there was no correlation between serum CRP level and cognitive impairment. This might be due to the inclusion of executive functions only in the cognitive assessment in the later study.
There was a statistically significant negative correlation between the serum CRP levels and the negative subscale of PANSS and the total PANSS score. However, no significant correlation was found between the serum CRP levels and the positive and general psychopathology subscales of PANSS. These findings were partially consistent with Fan et al. (2007) and Boozalis et al. (2018), who showed that there was a significant correlation between serum CRP levels and negative and general psychopathology subscales. Another study showed that serum CRP levels were associated with more severe psychopathology represented by higher PANSS scores (Fawzi et al., 2011).
Our findings were inconsistent with other studies that found no correlation between serum CRP levels and PANSS scores (Faugere et al., 2015; Fernandes et al., 2016). One of these studies showed that the extent of the increase in peripheral CRP levels paralleled the increase in the severity of positive symptoms, but was unrelated to the severity of negative symptoms, these inconsistencies might be due to the huge differences regarding the sample size between the studies. It might also be due to differences in the sex distribution, duration of untreated illness, and the use of medications and inclusion of untreated patients such as the study conducted by Fernandes et al. (2016).
By using multivariate linear regression, we found that there was a significant inverse relation between MoCA-B and CRP after adjustment for the duration of illness, age, sex, and smoking as possible confounders, which seconds the effect of inflammation that might be related to cognitive deficits in SZ (Misiak et al., 2018).
| Conclusions|| |
To sum up, our research is the first study in Egypt that investigated the relation between serum CRP with different cognitive domains using MoCA-B and with the severity of symptoms in a sample of patients suffering from SZ.
Serum CRP level was elevated in patients with SZ when compared with healthy controls and significantly negatively correlated to cognitive functions and positively correlated with negative symptoms in SZ patients, which seconds the neuroinflammatory etiology of SZ. Altogether, with the literature, we suggest that abnormal CRP may be considered as a peripheral biomarker of cognitive impairment in SZ.
Being a cross-sectional study makes it one of the limitations that hindered us to determine the cause-and-effect relationship. Also, multicenter studies with larger sample sizes are also recommended to demonstrate generalizability of our current findings.
Finally, longitudinal studies are necessarily needed to assess the change in cognitive functions in patients with SZ across the course of their illness and studying their correlation with serum CRP levels at various intervals and to assess the role of anti-inflammatory treatment in amelioration of the various symptoms of SZ.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Akbar NL, Effendy E, Camellia V (2019). The Indonesian Version of Montreal Cognitive Assessment (MoCA-Ina): the difference scores between male schizophrenia prescribed by risperidone and adjunctive of donepezil in Public Hospital of Dr Pirngadi Medan, Indonesia. Open Access Maced J Med Sci 7:1762.
Aleman A, Hijman R, de Haan EHF, Kahn RS (1999). Memory impairment in schizophrenia: a meta-analysis. Am J Psychiatry 156:1358–1366.
Berberian AA, Moraes GV, Gadelha A, Brietzke E, Fonseca AO, Scarpato BS, Lacerda AL (2016). Is semantic verbal fluency impairment explained by executive function deficits in schizophrenia?. Braz J Psychiatry 38:121–126.
Boozalis T, Teixeira AL, Cho RYJ, Okusaga O (2018). C-Reactive protein correlates with negative symptoms in patients with schizophrenia. Front Public Health 5:360.
Bozikas VP, Kosmidis MH, Kiosseoglou G, Karavatos A (2006). Neuropsychological profile of cognitively impaired patients with schizophrenia. Compr Psychiatry 47:136–143.
Brébion G, Villalta-Gil V, Autonell J, Cervilla J, Dolz M, Foix A, Ochoa S (2013). Cognitive correlates of verbal memory and verbal fluency in schizophrenia, and differential effects of various clinical symptoms between male and female patients. Schizophr Res 147:81–85.
Bulzacka E, Boyer L, Schürhoff F, Godin O, Berna F, Brunel L, Chesnoy-Servanin G (2016). Chronic peripheral inflammation is associated with cognitive impairment in schizophrenia: results from the multicentric FACE-SZ dataset. Schizophr Bull 42:1290–1302.
Chan MW, Yip JT, Lee TM (2004). Differential impairment on measures of attention in patients with paranoid and nonparanoid schizophrenia. J Psychiatr Res 38:145–152.
Daradkeh TK, Ghubash R, El-Rufaie OEF (2001). Reliability, validity and factor structure of the Arabic version of the 12-item General Health Questionnaire. Psychol Rep 89:85–94.
Dickerson F, Stallings C, Origoni A, Vaughan C, Khushalani S, Yang S, Yolken R (2013). C-reactive protein is elevated in schizophrenia. Schizophr Res 143:198–202.
Diyanoosh N, Rezaei O, Masafi S, Nazeri A, Hoseynzade H (2012). Relationship of blood C-reactive protein (CRP) level and cognitive deficit in patients with schizophrenia. Int J Collab Res Intern Med Public Health 4:XX.
El Missiry A, Sorour A, Sadek A, Fahy T, Abdel Mawgoud M, Asaad T (2004). Homicide and psychiatric illness: an Egyptian study. MD thesis. Cairo: Faculty of Medicine, Ain Shams University.
Fan X, Pristach C, Liu EY, Freudenreich O, Henderson DC, Goff DC (2007). Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Res 149:267–271.
Faugere M, Micoulaud-Franchi JA, Alessandrini M, Richieri R, Faget-Agius C, Auquier P, Boyer L (2015). Quality of life is associated with chronic inflammation in schizophrenia: a cross-sectional study. Sci Rep 5:1–7.
Fawzi MH, Fawzi MM, Fawzi MM, Said NS (2011). C-reactive protein serum level in drug-free male Egyptian patients with schizophrenia. Psychiatry Res 190:91–97.
Fernandes BS, Steiner J, Bernstein HG, Dodd S, Pasco JA, Dean OM, Berk M (2016). C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications. Mol Psychiatry 21:554–564.
Fioravanti M, Bianchi V, Cinti MA (2012). Cognitive deficits in schizophrenia: an updated metanalysis of the scientific evidence. BMC Psychiatry XX:22–34.
First MB, Gibbon M, Spitzer RL, Williams JBW, Benjamin LS (1997). Structured clinical interview for DSM-IV axis II personality disorders, (SCID-II). Washington, DC: American Psychiatric Association.
Fisekovic S, Memic A, Pasalic A (2012). Correlation between moca and mmse for the assessment of cognition in schizophrenia. Acta Inform 20:186–189.
Fourrier C, Singhal G, Baune B (2019). Neuroinflammation and cognition across psychiatric conditions. CNS Spectr 24:4–15.
Fraguas D, Diaz-Caneja CM, Pina-Camacho L, Janssen J, Arango C (2014) Progressive brain changes in children and adolescents with early-onset psychosis: a meta-analysis of longitudinal MRI studies. Schizophr Res; XX:XX.
Gil-Berrozpe GJ, Sánchez-Torres AM, de Jalón García E et al.
(2020). Utility of the MoCA for cognitive impairment screening in long-term psychosis patients. Schizophr Res 216:429–434.
Horning S, Davis HP (2012). Aging and cognition. Encyclopedia of Human Behavior 2:44–52.
Joseph J, Depp C, Martin AS, Daly RE, Glorioso DK, Palmer BW, Jeste DV (2015). Associations of high sensitivity C-reactive protein levels in schizophrenia and comparison groups. Schizophr Res 168:456–460.
Kay SR, Fiszbun A, Opler LA (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13:261–276.
Lakhan SE, Vieira K, Hamlat E (2010). Biomarkers in psychiatry: drawbacks and potential for misuse. Int Arch Med 3:1.
Liu KC, Chan RC, Chan KK, Tang JY, Chiu CP, Lam MM, Chen EY (2011). Executive function in first-episode schizophrenia: a three-year longitudinal study of an ecologically valid test. Schizophr Res 126:87–92.
Mazzarello V, Cecchini A, Fenu G, Rassu M, Dessy LA, Lorettu L, Montella A (2004). Lymphocytes in schizophrenic patients under therapy: serological, morphological and cell subset findings. Ital J Anat Embryol 109:177–188.
Meyer URS, Schwarz MJ, Müller N (2011). Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. Pharmacol Ther 132:96–110.
Miller BJ, Culpepper N, Rapaport MH (2013). C-reactive protein levels in schizophrenia: a review and meta-analysis. Clin Schizophr Relat Psychoses 7:223–230.
Minzenberg MJ, Yoon JH, Carter CS, Hales RE, Yudofsky SC, Gabbard GO (2008). American psychiatric publishing textbook of psychiatry
Misiak B, Stańczykiewicz B, Kotowicz K, Rybakowski JK, Samochowiec J, Frydecka D (2018). Cytokines and C-reactive protein alterations with respect to cognitive impairment in schizophrenia and bipolar disorder: a systematic review. Schizophr Res 192:16–29.
Monji A, Kato T, Kanba S. (2009). Cytokines and schizophrenia: microglia hypothesis of schizophrenia. Psychiatry Clin Neurosci 63:257–265.
Oertel-Knöchel V, Bittner RA, Knöchel C, Prvulovic D, Hampel H (2011). Discovery and development of integrative biological markers for schizophrenia. Prog Neurobiol 95:686–702.
Ohaer JU, Hedo CC, Langundoye OO (1993). The profile of C-reactive proteins in psychotic state in a cohort in Nigeria. Acta Psychiatr Scand 88:252–255.
Orellana G, Slachevsky A (2013). Executive functioning in schizophrenia. Front Psychiatry 4:35.
Potvin S, Stip E, Sepehry AA et al.
(2008). Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 63:801–808.
Saleh AA, Alkholy RS, Khalaf OO et al.
(2019). Validation of Montreal Cognitive Assessment-Basic in a sample of elderly Egyptians with neurocognitive disorders. Aging Ment Health 2019; 23:551–557.
Savla GN, Twamley EW, Delis DC, Roesch SC, Jeste DV, Palmer BW (2012). Dimensions of executive functioning in schizophrenia and their relationship with processing speed. Schizophr Bull 38:760–768.
Singh B, Chaudhuri TK (2014). Role of C-reactive protein in schizophrenia: an overview. Psychiatry Res 216:277–285.
Solanki RK, Singh P, Singh M, Sinha M, Swami MK, Saini S (2009). C-reactive protein (CRP) in patients with schizophrenia: are they related with symptomatology. J Mental Health Hum Behav 15:6–10.
Sponheim RE, Jung LJ, Seidman RI, Mesholam-Gately DS, Manoach DS, O’Leary BC et al.
(2010). Cognitive deficits in recent-onset and chronic schizophrenia. J Psychiatr Res 44:421–428.
Wersching H, Duning T, Lohmann H et al.
(2010) Serum C-reactive protein is linked to cerebral microstructural integrity and cognitive function. Neurology 74:1022–1029.
Yang Z, Rashid NAA, Quek YF, Lam M, See YM, Maniam Y, Lee J (2018). Montreal Cognitive Assessment as a screening instrument for cognitive impairments in schizophrenia. Schizophr Res 199:58–63.
Zahran NS, Khalil AH, Okasha TA et al.
(2006). Systematic review of Egyptian studies on schizophenia. Master thesis. Ain Shams University.
[Table 1], [Table 2], [Table 3], [Table 4]